InSilixa InSilixa is a company producing CMOS (complementary metal-oxide-semiconductor) biochips for microarray technology, qPCR (quantitative polymerase chain reaction), and DNA sequencing. | ![]() Intersect ENT Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company. | |||
Founding Date | Founding Date 2011 | Founding Date 2011 | Founding Date 1982 | Founding Date 2003 |
Type | Type Subsidiary | Type Private | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Paris, FR HQ | Locations Sunnyvale, US HQ | Locations Macquarie Park, AU HQ Wien, AT Mechelen, BE Toronto, CA Beijing, CN Prague, CZ Vantaa, FI see more | Locations Menlo Park, US HQ |
Employees | Employees 30 | Employees 7 | Employees 4,996 | Employees 4337% increase |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2.4b (FY, 2025) | Revenue (est.) $106.7m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $524.8m (FY, 2025) | Cost of goods $30m (FY, 2021) |
Gross profit | Gross profit €2m (FY, 2022) | Gross profit N/A | Gross profit $1.9b (FY, 2025) | Gross profit $76.7m (FY, 2021) |
Net income | Net income (€10.3m) (FY, 2022) | Net income N/A | Net income $388.9m (FY, 2025) | Net income ($159.6m) (FY, 2021) |
Funding | ||||
Total funding raised | Total funding raised $ 19.3m | Total funding raised $ 13m | Total funding raised N/A | Total funding raised $ 102.9m |
InSilixa is a company producing CMOS (complementary metal-oxide-semiconductor) biochips for microarray technology, qPCR (quantitative polymerase chain reaction), and DNA sequencing.
View company
Cochlear is a company developing implantable hearing solutions.
View company
Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company.
View company